GlassScriptPhysician profile
Abigail Weirauch
NPI 1508465543
$3,098.39
in general payments reported to CMS, 2019-2025
27 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $532 · 2023: $698 · 2024: $744 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.29 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.23 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $412.63 | 2021-2025 | |
| Lilly USA, LLC | $294.83 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $257.71 | 2021-2024 | Veozah |
| Neurocrine Biosciences, INC. | $243.44 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $227.52 | 2022-2024 | Auvelity |
| Amgen INC. | $213.52 | 2021-2025 | Krystexxa, Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $200.81 | 2023-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $122.05 | 2021-2024 | Breztri, Airsupra |
| Lundbeck LLC | $110.31 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $77.88 | 2022-2025 | |
| Glaxosmithkline, LLC. | $74.37 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $53.38 | 2022 | |
| Pfizer INC. | $48.32 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $43.69 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.64 | 2025 | Cologuard Collection Kit |
| Organon LLC | $38.11 | 2023 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.82 | 2023 | |
| Bioventus LLC | $19.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.73 | 2023 | |
| Owp Pharmaceuticals, INC. | $17.03 | 2024 | Subvenite |
| Biohaven Pharmaceuticals, INC. | $16.87 | 2021 | |
| Gilead Sciences, INC. | $16.25 | 2023 | |
| Dexcom, INC. | $14.52 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.96 | 2021 | |
| Antares Pharma, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Weirauch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.